Aspergillose pulmonaire aiguë invasive et pathologies ... - SPLF

F. Ader et coll.their responsivness to gamma interferon. J Clin Invest 1985 ; 76 :1755-64.18 Barczyk A, Sozanska E, Trzaska M, Pierzchala W : Decreased levels ofmyeloperoxidase in induced sputum of patients with COPD aftertreatment with oral glucocorticoids. Chest 2004 ; 126 : 389-93. Erratumin Chest 2005 ; 127 : 415.19 Barnes PJ, Shapiro SD, Pauwels RA : Chronic obstructive pulmonarydisease: molecular and cellular mechanisms. Eur Respir J 2003 ; 22 :672-88.20 Wilson DO, Rogers RM, Hoffmann RM : State of the art: nutritionand chronic lung disease. Am Rev Respir Dis 1985 ; 132 : 1347-65.21 Latgé JP : Aspergillus fumigatus and aspergillosis. Clin Microbiol Rev1999 ; 12 : 310-50.22 Aldebert D, Pinel C, Brion JP, Ambroise-Thomas P, Grillot R : Lerôle de l’immunité locale dans l’aspergillose pulmonaire invasive.Presse Med 2001 ; 30 : 1258-64.23 Philippe B, Ibrahim-Granet O, Prevost MC, Gougerot-Pocidalo MA,Sanchez-Perez M, Van der Meeren A, Latgé JP : Killing of Aspergillusfumigatus by alveolar macrophages is mediated by reactive oxidantintermediates. Inf Immun 2003 ; 71 : 3034-42.24 Shoham S, Levitz SM : The immune response to fungal infections.Brit J Haematol 2005 ; 129 : 569-82.25 Diamond RD : Inhibition of monocyte-mediated damage to fungalhyphae by steroid hormones. J Infect Dis 1983 ; 147 : 160.26 Jantz MA, Sahn SA : Corticosteroids in acute respiratory failure Am JCrit Care Med 1999 ; 160 : 1079-1100.27 Augusti C, Rano A, Fillela X, Gonzalez J, Moreno A, Xaubet A,Torres A : Pulmonary infiltrates in patients receiving long-term glucocorticoidtreatment. Chest 2003 ; 123 : 488-98.28 Tony TC, Robson GD, Denning DW : Hydrocortisone-enhancedgrowth of Aspergillus spp: implications for pathogenesis. Microbiology1994 ; 140 : 2475-9.29 Leav BA, Fanburg B, Hadley S : Invasive pulmonary aspergillosisassociated with high-dose inhaled fluticasone. N Engl J Med 2000 ;343 : 586.30 Peter E, Bakri F, Ball DM, Cheney RT, Segal BH : Invasive pulmonaryfilamentous fungal infection in a patient receiving inhaled corticosteroidtherapy. Clin Infect Dis 2002 ; 35 : e54-e56.31 Perfect JR, Cox GM, Lee JY, Kauffman CA, de Repentigny L,Chapman SW, Morrison VA, Pappas P, Hiemenz JW, Stevens DA.Mycoses Study Group : The impact of culture isolation of Aspergillusspecies: a hospital-based survey of aspergillosis. Clin Infect Dis 2001 ;33 : 1824-33.32 Uffredi ML, Mangiapan G, Cadranel J, Kac G : Significance ofAspergillus fumigatus isolation from respiratory specimens of nongranulocytopenicpatients. Eur J Clin Microbiol Infect Dis 2003 ; 22 : 457-62.33 Maertens J, Verhaegen J, Lagrou K, Van Eldere J, Boogaerts M :Screening for circulating galactomannan as a non-invasive diagnostictol for invasive aspergillosis in prolonged neutropenic patients andstem cell transplantation recipients: a prospective validation. Blood2001 ; 97 : 1604-10.34 Denning DW : Early diagnosis of invasive aspergillosis. The Lancet2000 ; 355 : 423-4.35 Husain S, Kwak EJ, Obman A, Wagener MM, Kusne S, Stout JE,McCurry KR, Singh N : Prospective assessment of Platelia Aspergillusgalactomannan antigen for the diagnosis of invasive aspergillosisin lung transplant recipients. Am J Transplant 2004 ; 4 : 796-802.36 Adam O, Aurépin A, Wilquin F, Bourhis JH, Gachot B, Chachaty E :Treatment with piperacillin-tazobactam and false-positive Aspergillusgalactomannan antigen test results for patients with hematologicalmalignancies. Clin Infect Dis 2004 ; 38 : 917-20.37 Caillot D, Couaillier JF, Bernard A, Casasnovas O, Denning DW,Mannone L, Lopez J, Couillault G, Piard F, Vagner O, Guy H :Increasing volume and changing characteristics of invasive pulmonaryaspergllosis on sequential thoracic computed tomography scans inpatients with neutropenia. J Clin Oncol 2001 ; 19 : 253-9.38 Greene RE, Schlamm HT, Stark P, the Global Aspergillus StudyGroup and the Invasive Fungal infection Group of the ORTC.Radiologic findings in acute invasive pulmonary aspergillosis: utilityand reliability of halo sign and air-crescient sign for diagnosis andtreatment of IPA in high risk patients [Abstract]. 13 th European Congressof Clinical Microbiology and Infectious Diseases, Glasgow, May10-13, 2003.39 SFAR, SPILF, SRLF, Société Française d’Hématologie, Société Françaisede Mycologie Médicale, Société Française de Greffe de Moelle :Prise en charge des candidoses et aspergilloses invasives de l’adulte.Rev Pneumol Clin 2004 ; 60 : 289-93.40 Horvath JA, Dummer S : The use of respiratory-tract cultures in thediagnosis of invasive pulmonary aspergillosis. Am J Med 1996 ; 100 :171-8.41 Levy H, Horak DA, Tegtmeier BR, Yokota SB, Forman SJ : Thevalue of bronchoalveolar lavage and bronchial washings in the diagnosisof invasive pulmonary aspergillosis. Respir Med 1992 ; 86 :243-8.42 Herbrecht R, Denning DW, Patterson TF, Bennett JE, Greene RE,Oestmann JW, Kern WV, Marr KA, Ribaud P, Lortholary O,Sylvester R, Rubin RH, Wingard JR, Stark P, Durand C, Caillot D,Thiel E, Chandrasekar PH, Hodges MR, Schlamm HT, Troke PF,dePauw B: Invasive Fungal Infections Group of the EuropeanOrganisation for Research and Treatment of Cancer and the GlobalAspergillus Study Group : Voriconazole versus amphotericin B forprimary therapy of invasive aspergillosis. N Engl J Med 2002 ; 347 :408-15.43 Leenders AC, Daenen S, Jansen RL Hop WC, Lowenberg B,Wijermans PW, Cornelissen J, Herbrecht R, van der Lelie H,Hoogsteden HC, Verbrugh HA, de Marie S : Liposomal amphotericinB compared with amphotericin B deoxycholate in the treatmentof documented and suspected neutropenia-associated invasive fungalinfections. Br J Haematol 1998 ; 103 : 205-12.44 Alfandari S, Leroy O, de Botton S, Yakoub-Agha I, Durand-Joly I,Leroy-Cotteau A, Beaucaire G : Management of aspergillosis inimmunocompromised patients. Recommendations of Lille UniversityHospital – 4 th version – November 2004. Med Mal Inf 2005 ; 35 :121-34.45 Maertens J, Raad I, Petrikkos G, Boogaerts M, Selleslag D,Petersen FB, Sable CA, Kartsonis NA, Ngai A, Taylor A,Patterson TF, Denning DW, Walsh TJ, Caspofungin Salvage AspergillosisStudy Group : Efficacy and safety of caspofungin for treatmentof invasive aspergillosis in patients refractory to or intolerant ofconventional antifungal therapy. Clin Infect Dis 2004 ; 39 : 1563-71.46 Bernard A, Caillot D, Couaillier JF, Casasnovas O, Guy H, Favre JP :Surgical management of invasive pulmonary aspergillosis in neutropenicpatients. Ann Thor Surg 1997 ; 64 : 1441-7.6S20Rev Mal Respir 2006 ; 23 : 6S11-6S20